Clinical Trial

Detection of Cardiac Amyloidosis Using Right Ventricular Sensing Amplitude in Patients With Left Ventricular Hypertrophy

Study acronym: DETECT-AMY
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This multicenter prospective study aims to evaluate the diagnostic performance of right ventricular sensing amplitude measured during cardiac implantable electronic device (CIED) implantation (pacemaker or defibrillator) to identify cardiac amyloidosis in patients with left ventricular hypertrophy and conduction abnormalities. Patients aged 65 years or older referred for CIED implantation will be included. During the procedure, electrophysiological parameters will be recorded. Additional assessments will be performed, including cardiac scintigraphy, biological analyses, and subcutaneous adipose tissue biopsy. The results of these investigations will be used to confirm or rule out cardiac amyloidosis. Diagnostic performance will be assessed using the area under the receiver operating characteristic curve (AUROC).
Trial Details
NCT Number NCT07734285
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Cardiac Amyloidosis, Left Ventricular Hypertrophy, Conduction Abnormality
Enrollment 242 participants
Start Date 2026-09-01
Primary Completion 2029-12-01 (estimated)
Study Completion 2030-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-29